Future work could leverage organoid models derived from patient tumor tissues to test the differential responses of high- and low-MLEM groups to immunotherapy (e.g., PD-1/PD-L1 inhibitors) and chemotherapeutics (e.g., vincristine). This evidence concerns the gene CD274 and neoplasm.